Omalizumab in chronic urticaria: a retrospective series of 15 cases

Armengot‐Carbó, Miquel; Velasco-Pastor, Manuel; Rodrigo-Nicolás, Beatriz; Pont-Sanjuan, Virginia; Quecedo-Estébanez, Esther; Gimeno-Carpio, E.

doi:10.1111/j.1529-8019.2013.01549.x

Cited by 20 publications

(16 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further evidence of omalizumab efficacy was seen in two studies, the first in Spain and the second in France, both published in 2013. The Spanish study evaluated the effectiveness of omalizumab in 15 patients with CIU, 12 of whom responded within the first 3 months of treatment (three with complete response and nine with partial response) . At month 6, eight of 10 patients who continued omalizumab therapy had a complete response, with the two others having a partial response.…”

Section: Resultsmentioning

confidence: 94%

“…The Spanish study evaluated the effectiveness of omalizumab in 15 patients with CIU, 12 of whom responded within the first 3 months of treatment (three with complete response and nine with partial response). 17 At month 6, eight of 10 patients who continued omalizumab therapy had a complete response, with the two others having a partial response. On the other hand, the French study evaluated three patients with refractory chronic cold urticaria (CCU) and found the optimal dose and dosing interval to be a starting cycle of four subcutaneous injections of omalizumab 300 mg every 2 weeks, with subsequent injections given depending on the progression of the symptoms.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Omalizumab for the Treatment of Chronic Idiopathic Urticaria: Systematic Review of the Literature

et al. 2017

View full text Add to dashboard Cite

Omalizumab is recombinant humanized monoclonal antibody to immunoglobulin E. Guidelines for the treatment of chronic idiopathic urticaria (also known as chronic spontaneous urticaria) recommend the use of omalizumab as third-line therapy in addition to high doses of histamine receptor type 1 (H ) antihistamines when they are unsuccessful as first- and second-line therapy. We performed a systematic review of the literature to identify studies that evaluated the efficacy of omalizumab for the treatment of chronic idiopathic urticaria, in both controlled and real-world settings, to assess its potential role as a preferred therapy. The PubMed, ScienceDirect, LILACS (Latin American and Caribbean Health Sciences Literature), and Google Scholar databases were searched between January 1, 2000, and November 21, 2016. The search was limited to articles published in peer-reviewed journals in the English language, and 29 studies were included in this review. Omalizumab 300 mg administered every 4 weeks appears to be the most effective and safe dosage, with a rapid response time, for the treatment of chronic idiopathic urticaria, with few minor adverse effects, and appears to be safe in the offspring of pregnant patients who received the drug. However, as published studies of omalizumab are sparse, future studies are warranted. When findings are confirmed in larger studies, due to its efficacy, safety, and increased benefit/cost ratio, omalizumab could become the preferred method of treatment for chronic idiopathic urticaria in patients unresponsive to H antihistamines.

show abstract

Section: Resultsmentioning

confidence: 94%

mentioning

confidence: 99%

Omalizumab for the Treatment of Chronic Idiopathic Urticaria: Systematic Review of the Literature

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Three (11.1%) patients were completely symptom-free and were able to discontinue treatment with omalizumab. Concurrently, Arment-Carbo et al [14] presented a case series of 15 patients treated with omalizumab of whom eight patients reported complete response after 6 months of treatment, although three out of the eight patients were only able to achieve complete response after an increase of omalizumab from 150 to 300 mg. Other real-life studies also suggested an individualized dosing regimen as the most efficient treatment plan [4,18]. Notably, a retrospective study by Metz et al [25••] of 25 patients with CSU and/or CINDU (mean age 45 years) investigated the response to omalizumab during retreatment.…”

Section: Dosing Regimensmentioning

confidence: 94%

“…The proportion of patients with no or very limited response to omalizumab in the 13 identified studies was, on average 15% (lowest 2% [18], highest 33% [14,16]). …”

Section: Main Findingsmentioning

confidence: 97%

Omalizumab for Chronic Urticaria: Aftermarket Reports of Efficacy and Side Effects

Ghazanfar

Thomsen

2017

Curr Derm Rep

View full text Add to dashboard Cite

Purpose of Review The purpose of this study was to review real-life studies on effectiveness and safety of omalizumab in chronic urticaria (CU). Recent Findings CU is an itching skin disease characterized by wheals, angioedema, or both (present >6 weeks). Omalizumab is a humanized anti-IgE monoclonal antibody approved for treatment of CU and is becoming one of the main treatment options for antihistamine-resistant CU; however, real-life studies on long-term effectiveness and safety are lacking. Summary We present an overview of the real-life literature totaling 505 patients with an age range of 7-82 years, on the effectiveness and safety of omalizumab used for CU since 2013. A complete response to omalizumab was seen among 64% of the patients, whereas 25% obtained partial response. On average, 15% had no or very limited response. Fifteen patients from five studies reported side effects. Overall, omalizumab was effective and well-tolerated for patients with antihistamine-resistant CU.

show abstract

“…Partial response (PR) Resolution or improvement of symptoms with the addition of antihistamines (Armengot-Carbo et al, 2013).…”

Section: Definitionsmentioning

confidence: 99%

Angioedema is an unfavorable factor for the response to omalizumab in chronic spontaneous urticaria: A retrospective study

Serarslan

Uzun

Doğramacı

et al. 2018

Dermatologic Therapy

View full text Add to dashboard Cite

Antihistamines are the first-line treatment option for chronic urticaria. In recent years, omalizumab, an anti-immunoglobulin-E humanized monoclonal antibody, has been used in patients with recalcitrant disease. The present study aimed to retrospectively evaluate the efficacy and safety of omalizumab and determine whether there was a difference between complete and partial responses to omalizumab with respect to age, gender, disease duration and coexistence of angioedema. From May 2014 to December 2016, a total of 40 refractory chronic urticaria patients were treated with omalizumab. Complete response was observed in 19 (47.5%) patients, and partial response was observed in 18 (45%) patients. There were no statistically significant differences between the rates of complete and partial responses in patients with respect to gender, age, and disease duration. However, complete response was more frequent (60%) in patients without angioedema. Remission was observed in 40.5% (n = 15) of patients, and the follow-up time was 5.5 AE 2.4 months. There was a statistically significant association between remission and coexistence of angioedema (p < .05). Eighty-seven percent (13/15) of the remission patients did not have angioedema. Thus, omalizumab can be used effectively and safely in refractory chronic urticaria patients. However, the coexistence of angioedema may be an unfavorable factor for complete response and remission.

show abstract

Omalizumab in chronic urticaria: a retrospective series of 15 cases

Cited by 20 publications

References 6 publications

Omalizumab for the Treatment of Chronic Idiopathic Urticaria: Systematic Review of the Literature

Omalizumab for the Treatment of Chronic Idiopathic Urticaria: Systematic Review of the Literature

Omalizumab for Chronic Urticaria: Aftermarket Reports of Efficacy and Side Effects

Angioedema is an unfavorable factor for the response to omalizumab in chronic spontaneous urticaria: A retrospective study

Contact Info

Product

Resources

About